Page last updated: 2024-12-08

n(6)-(n-threonylcarbonyl)adenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6)-(N-threonylcarbonyl)adenosine: anticodon adjacent nucleoside; occurs at3'end of anticodon in most tRNA's whih read codons beginning with adenosine;RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine : An N-(adenosin-N(6)-ylcarbonyl)threonine in which the threonine portion has L-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID161466
CHEBI ID21440
SCHEMBL ID63155
MeSH IDM0044277

Synonyms (32)

Synonym
24719-82-2
t(6)a
n(6)-(n-threonylcarbonyl)adenosine
(2s,3r)-2-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]carbamoylamino]-3-hydroxybutanoic acid
n-(purin-6-ylcarbamoyl)-l-threonine riboside
3c55p4w4tb ,
l-threonine, n-(((9-beta-d-ribofuranosyl-9h-purin-6-yl)amino)carbonyl)-
unii-3c55p4w4tb
n-((9-beta-d-ribofuranosylpurin-6-yl)-carbamoyl)threonine
n6-threonylcarbamoyladenosine
n6-carbamoyl-l-threonyladenosine
n-[(9-beta-d-ribofuranosylpurin-6-yl)carbamoyl]-l-threonine
CHEBI:21440
n6-carbamoylthreonyladenosine
n-[(9-beta-d-ribofuranosylpurin-6-yl)carbamoyl]threonine
n-{[(1s,2r)-1-carboxy-2-hydroxypropyl]carbamoyl}adenosine
t6a ,
SCHEMBL63155
n6-threoninocarbonyladenosine
(2s,3r)-2-[({9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purin-6-yl}carbamoyl)amino]-3-hydroxybutanoic acid
n6-[((1s,2r)-1-carboxy-2-hydroxybutylamino)carbonyl]adenosine sodium salt
((9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purin-6-yl)carbamoyl)-l-threonine
(2s,3r)-2-(3-(9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purin-6-yl)ureido)-3-hydroxybutanoic acid
Q15632802
n-(((9-.beta.-d-ribofuranosyl-9h-purin-6-yl)amino)carbonyl)-l-threonine
n6-carbamoylthreonyl adenosine
n-((9-.beta.-d-ribofuranosyl-9h-purin-6-yl)carbamoyl)-l-threonine
n6-(n-threonylcarbonyl)adenosine
DTXSID70947655
n-{hydroxy[(9-pentofuranosyl-9h-purin-6-yl)amino]methylidene}threonine
STARBLD0012987
AKOS040754126
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
N-(adenosin-N(6)-ylcarbonyl)threonineN-(adenosin-N(6)-ylcarbonyl)threonine and derivatives thereof.
L-threonine derivativeA proteinogenic amino acid derivative resulting from reaction of L-threonine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-threonine by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (14.89)18.7374
1990's3 (6.38)18.2507
2000's5 (10.64)29.6817
2010's27 (57.45)24.3611
2020's5 (10.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.75 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index5.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (95.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]